Cancer stem cell isolation

Patent metadata

Field	Value
Publication number	US-10018630-B2
Application number	US-201214343364-A
Country	US
Kind code	B2
Filing date	Sep 7, 2012
Priority date	Sep 7, 2011
Publication date	Jul 10, 2018
Grant date	Jul 10, 2018

Abstract

An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same. The present inventors discovered that highly pure colon cancer stem cells (CSC) can be obtained in a large quantity, and identified two types of states of colon CSCs distinguishable through Lgr5 expression.

First claim

The invention claimed is:

1. An isolated cancer stem cell, wherein the cancer stem cell is
a) of human origin;
b) positive for Lgr5, ALDH activity cell marker, LCK, FGFBP1, ROR1 and PIGU;
c) adherent in serum free culture;
d) generated by grafting a cancer into a non-human animal and passaging; and
e) regenerates the hierarchical order of human cancer.

2. The cancer stem cell of claim 1 , which is a mesenchymal cell.

3. The cancer stem cell of claim 1 , which is derived from a gastrointestinal cancer.

4. The cancer stem cell of claim 3 , wherein the gastrointestinal cancer is a large intestine cancer.

5. The cancer stem cell of claim 1 , which is positive for one or more of cell markers CD133, CD44, EpCAM, CD166, CD24, CD26, CD29, and EREG.

6. The cancer stem cell of claim 5 , which is positive for cell markers CD133, CD44, EpCAM, CD166, CD24, CD26, CD29, and EREG.

7. The cancer stem cell of claim 1 , which has the ability of epithelial-mesenchymal transition.

8. A homogeneous cancer stem cell population comprising the cancer stem cell of claim 1 .

Assignees

• Yamazaki Tatsumi
• Okabe Hisafumi
• Kobayashi Shinta
• Watanabe Takeshi
• Matsubara Koichi
• Kato Atsuhiko
• Suzuki Masami
• Chugai Pharmaceutical Co Ltd
• Pharmalogicals Res Pte Ltd

Inventors

• Yamazaki Tatsumi
• Okabe Hisafumi
• Kobayashi Shinta
• Watanabe Takeshi
• Matsubara Koichi
• Kato Atsuhiko
• Suzuki Masami

Classifications

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title

• A61P35/04

  specific for metastasis · CPC title

• G01N33/5073 Primary

  Stem cells · CPC title

• C12N5/0695

  Stem cells; Progenitor cells; Precursor cells · CPC title